Jennifer Kimberly Lue

Author

Columbia University Irving Medical Center ORCID

Also Known As

J Lue, J. K. Lue, J. Lue, J.K. Lue, Jeniffer K. Lue, Jennifer K Lue, Jennifer K. Lue, Jennifer Kimberly Lue, Jennifer Lue, Lue, J.

156

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Columbia University Irving Medical Center Moffitt Cancer Center Columbia University Memorial Sloan Kettering Cancer Center University of Washington

About

Jennifer Kimberly Lue is an author at Columbia University Irving Medical Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	354
2	Health Sciences	1	1	13
3	Cell Biology	1	1	31
4	Cellular Physiology	1	1	31
5	Cellular Therapies	1	1	173

Jennifer Kimberly Lue

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study Lorenzo Falchi, Helen Ma, Sandra E. Klein, Blood	2020	174
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission Daniel J. Landsburg, Marissa K. Falkiewicz, Joseph Maly, Journal of Clinical Oncology Lymphoid NeoplasiaDisease RelapseSurgical OncologyOncologyMarrow Transplantation	2017	173
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue, Blood	2017	128
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study Owen A. O’Connor, Lorenzo Falchi, Jennifer Kimberly Lue, Blood	2019	127
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas, The Lancet Oncology Lymphoid NeoplasiaRefractory HodgkinMedicinePathologyCancer Treatment	2017	113
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era James N. Gerson, Elizabeth A. Handorf, Diego Villa, Journal of Clinical Oncology	2019	94
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas Jennifer Kimberly Lue, Sathyen A. Prabhu, Yuxuan Liu, Clinical Cancer Research	2019	75
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma Jennifer E. Amengual, Jennifer Kimberly Lue, Helen Ma, The Oncologist	2021	53
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a <i>TP53</i> mutation Anita Kumar, Jacob D. Soumerai, Jeremy S. Abramson, Blood	2024	32
Mitochondrial Apoptosis-Induced Channel (MAC) Function Triggers a Bax/Bak-Dependent Bystander Effect Pablo M. Peixoto, Jennifer Kimberly Lue, Shin-Young Ryu, American Journal Of Pathology MitophagySignal TransductionMitochondrial FunctionPhysiologyApoptosis	2011	31

Page 1